Structure Therapeutics reports Q3 net loss $65.7M; aleniglipron data on track for year-end 2025

Structure Therapeutics Inc.

2025-Q3 EPS reported -$1.00

Net loss of $65.7M in Q3 2025 vs. $34.0M in Q3 2024; R&D expenses rose to $59.0M from $32.6M.
Cash, cash equivalents and short-term investments totaled $799.0M as of Sep 30, 2025, expected to fund operations through at least 2027.
Topline 36-week data from aleniglipron ACCESS and ACCESS II Phase 2 studies expected by year-end 2025.
Phase 1 study of oral amylin receptor agonist ACCG-2671 anticipated by year-end 2025; second amylin candidate ACCG-3535 declared.
GAAP net loss per share not disclosed; non-cash share-based compensation was $7.5M in Q3 2025.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.